Studies of Benign and Malignant Thyroid Disease
Studies of Benign and Malignant Thyroid Disease
批准号:
10931296
负责人:
Joanna Klubo-Gwiezdzinska
金额:
$36.66万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
ADAMTSAdultAgeB cell differentiationBehaviorBenignBlood specimenCD19 geneCarcinomaCodeCohort StudiesComplement 3d ReceptorsDevelopmentDiagnosisDiagnosticDistant MetastasisDown-RegulationExcisionFamilyFine needle aspiration biopsyG Protein-Coupled Receptor SignalingGenderGenesHistologyImmuneImmune responseIncidenceIndolentMS4A1 geneMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of thyroidMeasuresMembraneMethodsMolecularMolecular ProfilingMultiple Endocrine Neoplasia Type 2aNatural HistoryNeckNeoplasm MetastasisNoduleOperative Surgical ProceduresOutcomePAX5 genePCDH15 genePatient ParticipationPatientsPeptide HydrolasesPredisposing FactorPrimary NeoplasmPrognosisProtein Tyrosine KinaseProteinsProtocols documentationRNARadioactive IodineRecurrent diseaseRoleSamplingScanningSignal TransductionSpecimenStructureStudy SubjectTechniquesThyroid DiseasesThyroid GlandThyroid NoduleTight JunctionsTissue SampleTissuesUp-RegulationVoltage-Gated Potassium ChannelWith lateralityantigen bindingclinically significantdifferential expressionextracellulargene repressionimmunoglobulin receptorimmunohistochemical markerslymph nodesmembermolecular markerpatient screeningreceptor bindingresearch studystandard caretranscriptome sequencingtreatment responsetumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Background: Thyroid microcarcinomas (TMCs) are tumors measuring 1cm characterized by an indolent behavior. However, up to 10% of TMCs may present with clinically significant lymph node (LNM) or distant metastases (DM). The characterization of molecular signature of metastases-prone TMCs may help strategizing the management options.
Methods: We performed whole transcriptome sequencing on the RNA extracted from 95 tissue samples, using KAPA RNA HyperPrep Kit. Eleven samples failed quality check. Differential expression analysis was performed using the LCDB workflow, with adjusted p-value0.1 rendered significant.
Results: The study cohort consisted of 19 patients with lateral neck LNM and/or DM (N1b group) and 17 patients without metastases (N0/Nx). There was no difference in the histology breakdown (p=0.5), median primary tumor size (0.6cm vs 0.8cm, p=0.27), age (39y vs 46y, p=0.54), gender (p=0.32) between the study groups. There were 93 differentially expressed genes (DEGs) in the primary tumors of pN1b patients versus pN0/pNx (8-up and 85-down-regulated; padj0.1). Primary tumors from N1b group were characterized by a significant downregulation in antigen binding immune components (CD19, CD79A, CR2; log2FC>-2.6; padj<0.05), immunoglobulin receptor binding/structure (IGHV1,3,4-family, FCRLA; log2FC>-2.6; padj<0.05) or in the development and differentiation of B-cells (PAX5, MS4A1; log2FC>-2.7; padj<0.05), and a significant upregulation of integral components of the membrane (NUP210L, TMEM145; log2FC>2 and padj<0.05) and extracellular protease (ADAMTS4; log2FC>2; padj<0.05).
The paired analysis of LNM vs primary tumor revealed 518 DEGs (322-up and 196-down; padj 0.1). LNM were characterized by a significant downregulation of the genes coding for tight junction proteins (CLDN6, CLDN4; log2FC>-0.9; padj<0.001), components of voltage-gated potassium channels (KCNJ12, KCNA1; log2FC>-0.8; padj<0.05), and G-protein coupled receptor signaling (ARHGEF35, GPRC5A; log2FC>-0.5; padj<0.05), while the up-regulated genes included members of non-receptor tyrosine kinase families (BLK, TXK; log2FC>1.7; padj<0.01), immune components (MS4A1, CR2, FCRL2, FCMR; log2FC>1.9; padj<0.01) and integral membrane components (TMEM272, PCDH15, SHISAL2A; log2FC>1.7; padj<0.01).
Conclusions: TMCs associated with LNM and/or DM are characterized by dysregulated immune landscape compared with classic indolent TMCs, suggesting a decreased immune response as a factor predisposing to metastases. Metastatic lesions are characterized by decreased tight junctions that are involved in signal transduction as one of the hallmarks of progression.
期刊论文(24)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1089/ct.2022;34.161-164
发表时间:
2022-04
期刊:
Clinical thyroidology
影响因子:
--
作者:
[]
通讯作者:
DOI:
10.4155/fsoa-2017-0087
发表时间:
2018-01
期刊:
Future science OA
影响因子:
2.5
作者:
[Jonklaas J, Murthy S, Liu D, Klubo-Gwiezdzinska J, Krishnan J, Burman KD, Boyle L, Carrol N, Felger E, Loh YP]
通讯作者:
Loh YP
DOI:
10.1530/ec-17-0138
发表时间:
2017-10
期刊:
Endocrine connections
影响因子:
2.9
作者:
[Klubo-Gwiezdzinska J, Costello J Jr, Jensen K, Patel A, Tkavc R, Van Nostrand D, Burman KD, Wartofsky L, Vasko V]
通讯作者:
Vasko V
DOI:
10.1016/s2213-8587(21)00152-2
发表时间:
2021-08
期刊:
The lancet. Diabetes & endocrinology
影响因子:
--
作者:
[]
通讯作者:
DOI:
10.3389/fendo.2022.896287
发表时间:
2022
期刊:
FRONTIERS IN ENDOCRINOLOGY
影响因子:
5.2
作者:
[Gubbi, Sriram, Koch, Christian A., Klubo-Gwiezdzinska, Joanna]
通讯作者:
Klubo-Gwiezdzinska, Joanna
共 11 条
Somatostatin receptors in the diagnosis and treatment of thyroid cancer
-
批准号:10700681
-
项目类别:
-
资助金额:$24.8万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
Use of metformin in the treatment of thyroid cancer
-
批准号:10011331
-
项目类别:
-
资助金额:$52.26万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
Studies of Thyroid Function in Health and Disease
-
批准号:10011456
-
项目类别:
-
资助金额:$5.23万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
Somatostatin receptors in the diagnosis and treatment of thyroid cancer
-
批准号:9553303
-
项目类别:
-
资助金额:$30.44万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
Cross-talk between oncogene-driven signaling pathways and thyroid cancer metabolism
-
批准号:10700683
-
项目类别:
-
资助金额:$49.6万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
Cross-talk between oncogene-driven signaling pathways and thyroid cancer metabolism
-
批准号:10931300
-
项目类别:
-
资助金额:$54.99万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
Application of molecular diagnostics in thyroid cancer
-
批准号:10255253
-
项目类别:
-
资助金额:$46.76万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
Studies of Benign and Malignant Thyroid Disease
-
批准号:10700666
-
项目类别:
-
资助金额:$33.07万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
Studies of Thyroid Function in Health and Disease
-
批准号:10706218
-
项目类别:
-
资助金额:$8.27万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
Studies of Thyroid Function in Health and Disease
-
批准号:10255335
-
项目类别:
-
资助金额:$11.69万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
Somatostatin receptors in the diagnosis and treatment of thyroid cancer
-
批准号:10011325
-
项目类别:
-
资助金额:$20.91万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
Studies of Thyroid Function in Health and Disease
-
批准号:10931304
-
项目类别:
-
资助金额:$9.17万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
Somatostatin receptors in the diagnosis and treatment of thyroid cancer
-
批准号:10931298
-
项目类别:
-
资助金额:$27.5万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
Application of molecular diagnostics in thyroid cancer
-
批准号:10011330
-
项目类别:
-
资助金额:$20.91万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
Somatostatin receptors in the diagnosis and treatment of thyroid cancer
-
批准号:10255252
-
项目类别:
-
资助金额:$116.9万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
Studies of Benign and Malignant Thyroid Disease
-
批准号:10255334
-
项目类别:
-
资助金额:$11.69万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
Application of molecular diagnostics in thyroid cancer
-
批准号:10931299
-
项目类别:
-
资助金额:$54.99万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
Studies of Benign and Malignant Thyroid Disease
-
批准号:10011455
-
项目类别:
-
资助金额:$5.23万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
Application of molecular diagnostics in thyroid cancer
-
批准号:10700682
-
项目类别:
-
资助金额:$49.6万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
Studies of Thyroid Function in Health and Disease
-
批准号:9553338
-
项目类别:
-
资助金额:$7.61万
-
财政年份:--
-
负责人:Joanna Klubo-Gwiezdzinska
-
依托单位:
海外基金